

It is essential to highlight the weaknesses of the study, these having to do with its retrospective nature and the review of medical records, increasing the chance of information bias. These results are important in justifying a therapeutic approach to a payer in light of data on adherence to methotrexate and the use of Jaki or IL6 blockers as monotherapy. Including patients initiating treatment since 2013 allows us to see a population with characteristics representing current treatment trends.